Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009
Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Efficacy of roflumilast in the frequent exacerbation COPD phenotype Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009
Effects of roflumilast in highly symptomatic COPD patients Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012
Roflumilast N-oxide combined with PI3Kδ inhibitor improves the phenotype of early-onset COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Recommendations for bronchodilators and PDE4 inhibitors for prevention of exacerbations of COPD Source: International Congress 2017 – Treatment and prevention of COPD exacerbation Year: 2017
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006
Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Montelukast as add-on therapy in severe noninfectious COPD exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003
Physiological effects of roflumilast at rest and during exercise in COPD Source: Eur Respir J 2012; 39: 1104-1112 Year: 2012
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis Source: Annual Congress 2013 –COPD diagnosis Year: 2013
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001